Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, down -12.01% from the previous trading day, before settling in for the closing price of $9.99. Over the past 52 weeks, NKTR has traded in a range of $6.48-$22.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -3.00%. While this was happening, its average annual earnings per share was recorded -40.83%. With a float of $11.96 million, this company’s outstanding shares have now reached $12.41 million.
The extent of productivity of a business whose workforce counts for 61 workers is very important to gauge. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.59%, while institutional ownership is 64.58%. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.69% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.53, a number that is poised to hit -2.98 in the next quarter and is forecasted to reach -12.07 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
The latest stats from [Nektar Therapeutics, NKTR] show that its last 5-days average volume of 0.28 million was superior to 0.15 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 14.61%. Additionally, its Average True Range was 1.13.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 24.00%, which indicates a significant increase from 0.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.36% in the past 14 days, which was lower than the 96.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.99, while its 200-day Moving Average is $14.56.
